MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma

ABSTRACT:

SUBMITTER: Ruan J 

PROVIDER: S-EPMC12927050 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature